Navigation Links
Vaccine adjuvant uses host DNA to boost pathogen recognition
Date:4/5/2013

reveal the role that DNA plays.

The National Jewish Health team had previously shown that the process starts with a series of events similar to those that initiate responses to bacterial infections. Neutrophils, and other early responders in the immune system, flood into a site of potential infection, attack the foreign agent, in this case the alum vaccine, then quickly die in massive numbers.

Upon death the neutrophils release large amounts of DNA, which uncoils from its chromatin spools and acts somewhat like a net to entangle the foreign agent. Other cells then engulf the DNA-alum-vaccine complex. These antigen-presenting cells display small fragments of the vaccine on their surfaces for T-cells to recognize. T-cells drive the adaptive immune response, the one that recognizes and attacks the specific infectious agent, as opposed to the more general innate immune response.

T-cells are also the basis for effective vaccines. Some T-cells, and the B-cells stimulated by the T-cells, transform into memory cells once the infection has been cleared. Those memory cells help mount a quicker and stronger immune response if they see that organism again.

The National Jewish Health team showed that the DNA coating the adjuvant doubles the time that the T-cell engages the vaccine fragment on the surface of the antigen-presenting cell. When they added DNase to digest DNA, the T-cell engaged the vaccine fragment half as long, and the vaccine was less effective. Several of the findings were made possible by an innovative use of multi-photon microscopy to film the interaction of T-cells and antigen-presenting cells.

"The DNA makes the antigen-presenting cell stickier," said Amy McKee, PhD, Instructor at the University of Colorado, and lead author of the paper. "We believe that extended engagement provides a stronger signal to the T-cell, which makes the immune response more robust."

The researchers are not sure exactly what makes the antigen-presenting cel
'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Health
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Cleverly designed vaccine blocks H5 avian influenza in models
2. HPV vaccine trends point to failures in patient education, vaccine programs
3. Cancer vaccines self-sabotage, channel immune attack to injection site
4. Human trials for Streptococcus A vaccine
5. Novel aptamer boosts T cell-based immune response to therapeutic vaccines
6. Designer bacteria may lead to better vaccines
7. UMMS experts seek better flu vaccines
8. MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech
9. Vaccine offers promise as post-surgery treatment for pancreatic cancer patients
10. Texas Biomed files patent for a novel HIV vaccine strategy
11. RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... August 28, 2015 According to ... Market by Assessment Type (Pen & Paper Based, Hosted, ... Corporate Learning, Academic Research), Vertical and Region - Global ... Training Market to grow from USD 2.4 Billion in ... Compound Annual Growth Rate (CAGR) of 25.6% from 2015 ...
(Date:8/26/2015)... , August 26, 2015 ... Four, and Five Factor), Application (Travel & Immigration, Government, ... - Global Forecast to 2020", published by MarketsandMarkets, Multi-Factor ... by 2020, growing at a CAGR of 17.7% between ... and 82 F igures spread through 169 ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... tempers the killing activity of a specific group of immune ... attack tumor cells and cells infected by viruses. The key ... which has been known for a long time and which ... Dr. Armin Rehm together with immunologist Dr. Uta Hpken of ...
... cause plants to store GM proteins in special ,protein ... increasing the overall protein yield. Researchers writing in the ... the mechanism by which the synthetic biopolymer increases the ... a team of researchers from Agriculture and Agri-Food Canada ...
... Heidelberg, Germany, 6 August 2009 The European ... a new private pension plan for EMBO Fellows. The ... needs of highly mobile scientists. Post-doctoral researchers who ... enrolling in the pension plan from 1 January 2010. ...
Cached Biology News:Estrogen-dependent switch tempers killing activity of immune cells 2EMBO pioneers pension plan for internationally mobile postdoctoral researchers 2EMBO pioneers pension plan for internationally mobile postdoctoral researchers 3
(Date:8/31/2015)... ... 31, 2015 , ... Regulatory agencies have acknowledged impurities especially ... process. Thus, innovator companies must understand what will be needed in the drug ... been hosting multiple educational panels and seminars for experts to share advice concerning ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Food ... food and beverage processors, equipment manufacturers and leaders in the field of academia. ... weighing and formulation for manufacturers of bakery and snacks; beverages; dairy; meat, poultry ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for ... first commercially available new FDA approved system in the last 14 years, and the ... high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, ...
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a finalist for ... High Tech Awards. , Now in its 22nd year, this premier awards event celebrates ... across the nation and around the world. The OC Tech Alliance will announce all ...
Breaking Biology Technology:Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4
... is Superior to Placebo, Similar Efficacy to ... a Day, and Less Daytime Drowsiness, ... (Nasdaq:,CEPH) announced the pooled analysis of two ... (cyclobenzaprine,hydrochloride extended-release capsules), a new once-daily extended-release,skeletal ...
... Quantitative Research ... Worldwide, NEW YORK, ... of those fielded in the US and abroad -- were,conducted online last ... report, released today, indicates that Internet-based market,research -- once the orphan of ...
... Inc. (Nasdaq: ONXX ) today announced that it ... and full year 2007,financial results and provide a business ... Time (2:00 p.m. Pacific Time). Financial results,for the fourth ... released,earlier that day., Interested parties may access a ...
Cached Biology Technology:Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 2Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 3Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting 4Technology Transforms Market Research in Pharmaceutical Industry 2Technology Transforms Market Research in Pharmaceutical Industry 3Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast 2